Atopic dermatitis can significantly compromise a dog’s quality of life and is often frustrating. Given the complex pathophysiology of canine atopic dermatitis (CAD), therapy
must be individualized, taking into account factors such as genetics, nutrition and environmental influences. Oclacitinib, an immune-modulating drug, has demonstrated its clinical efficacy for both acute flares and chronic management of CAD. It provides reduction in pruritus and inflammations and offers faster onset of action.
Buddy Life in its April – June 2026 edition, published an indept article on Canine Atopic dermatitis, written by the regulatory team of Zenex Animal Health.
Related Media Coverage
